Report House of Commons Influence Pharmaceutical Industry 2004 http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/4202.htm http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/4202.htmContents

Terms of Reference

REPORT

Summary

1 Introduction

2 The UK pharmaceutical industry

 

Research and development

Medicines and health gains

Generic medicines

The Pharmaceutical Industry Competitiveness Task Force

3 Difficulties facing the pharmaceutical industry

4 From drug development to prescription

 

Drug development and the conduct of medical research

Medicines licensing

Post-licensing evaluation, including value for money assessments

The provision of medicines information

Information to prescribers

Information to patients

Professional and patient education

The promotion of drugs

5 Arrangements for controlling the activity of the UK-based pharmaceutical industry

 

International standards and 'good clinical practice' guidelines

Research Ethics Committees

Licensing: the MHRA

Post-licensing surveillance

Orphan drugs

The National Institute for Clinical Excellence

The Pharmaceutical Price Regulation Scheme

Drug and Therapeutics Committees

Professional bodies

The industry's codes of practice

6 Control of access to medicines

 

Drug classification

Prescribing

Doctors

Nurses

Pharmacists

7 Inappropriate level of industry influence?

8 Influence of the industry on key groups

 

Research into pharmaceuticals

Innovation and therapeutic advance

Conduct of medical research

Prescribers

The use of journals

Drug company promotional activities

Promotional campaigns: targeting of healthcare professionals

Advertising

Patients

Information to patients: the Internet and PILs

Disease awareness campaigns

Promotional campaigns: targeting patients and the general public

Patient organisations

The drug regulatory system

Reputation of the regulator

Post-marketing surveillance

The patient voice

Expert Working Group report on SSRI safety

Wider significance of the SSRI experience

Medicines reclassification

NICE

Government

9 Conclusions and recommendations

 

Conclusions

Unsafe use of drugs

Medicalisation of society: 'a pill for every ill'

Recommendations

The industry

The regulatory system

Medical practitioners

Patients

NICE

Government and EU

Annex: contributions from pharmaceutical companies to All-Party Groups

List of Abbreviations

Glossary

Conclusions and recommendations

Formal minutes

Witnesses

Reports from the Health Committee since 2001 MINUTES OF EVIDENCE - VOLUME II (HC 42-II)

Thursday 9 September 2004Thursday 14 October 2004Thursday 11 November 2004Thursday 25 November 2004Thursday 7 December 2004Thursday 16 December 2004Thursday 13 January 2005Tuesday 20 January 2005Thursday 3 February 2005 WRITTEN EVIDENCE - VOLUME II (HC 42-II)